Mason & Associates Inc Invests $245,000 in Novo Nordisk A/S (NYSE:NVO)

Mason & Associates Inc bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,060 shares of the company’s stock, valued at approximately $245,000.

Other hedge funds also recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC bought a new position in shares of Novo Nordisk A/S during the first quarter valued at approximately $128,000. Wealthcare Advisory Partners LLC increased its holdings in shares of Novo Nordisk A/S by 38.9% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 14,253 shares of the company’s stock valued at $1,830,000 after acquiring an additional 3,990 shares during the period. Franklin Street Advisors Inc. NC bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $206,000. Wealth Enhancement Advisory Services LLC boosted its position in Novo Nordisk A/S by 91.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 205,698 shares of the company’s stock valued at $26,412,000 after purchasing an additional 98,007 shares in the last quarter. Finally, Chesley Taft & Associates LLC grew its stake in Novo Nordisk A/S by 2.4% in the first quarter. Chesley Taft & Associates LLC now owns 4,245 shares of the company’s stock valued at $545,000 after purchasing an additional 100 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on NVO shares. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $1.49 during trading hours on Thursday, hitting $114.25. 2,011,277 shares of the company were exchanged, compared to its average volume of 4,274,492. The company’s 50 day moving average price is $127.52 and its 200-day moving average price is $131.50. The stock has a market capitalization of $512.70 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 1.54 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $92.94 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The company had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. As a group, research analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.